Key facts
- Catherine A. Sohn has 6 issuer positions tracked on this page.
- Estimated disclosed ownership value: $2,340,976.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Catherine A. Sohn
- Location
- Gaithersburg, MD
- Summary
- The estimated net worth of Catherine A. Sohn is at least $2,340,976 dollars as of 01 May 2026. Catherine A. Sohn is the Director of Jazz Pharmaceuticals plc and owns shares of Jazz Pharmaceuticals plc (JAZZ) stock worth about $1.77M. Catherine A. Sohn is the Director of LANDEC CORP \CA\ and owns shares of LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) stock worth about $563.4K. Catherine A. Sohn is the Director of Altimmune, Inc. and owns shares of Altimmune, Inc. (ALT) stock worth about $6.4K.
- Signature
- /s/ Gregory Weaver, as Attorney-in-Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Catherine A. Sohn and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
Change
- Largest disclosed position: Jazz Pharmaceuticals plc ($1,771,225).
- Past-year value change for that position: .
Research use
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Catherine A. Sohn
JAZZ
Forms 3/4/5
Jazz Pharmaceuticals plc
- Relationship
- Director
- Holdings value
- $1,771,225
- Past year net change
- Change %
- Report period
- 11 Aug 2023
LFCR
Forms 3/4/5
LANDEC CORP \CA\
- Relationship
- Director
- Holdings value
- $563,399
- Past year net change
- Change %
- Report period
- 04 Jun 2022
ALT
Forms 3/4/5
Altimmune, Inc.
- Relationship
- Director
- Holdings value
- $6,352
- Past year net change
- +$2,118
- Change %
- +50%
- Report period
- 01 May 2026
MAZE
Forms 3/4/5
Maze Therapeutics, Inc.
- Relationship
- Director
- Holdings value
- $0
- Past year net change
- -$1,149,054
- Change %
- -100%
- Report period
- 06 Jan 2026
AXLA
Forms 3/4/5
Axcella Health Inc.
- Relationship
- Director
- Holdings value
- Past year net change
- Change %
- Report period
- 19 May 2022
RUBY
Forms 3/4/5
Rubius Therapeutics, Inc.
- Relationship
- Director
- Holdings value
- Past year net change
- Change %
- Report period
- 12 May 2022
Insider Transactions Reported by Catherine A. Sohn:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.